SCLX | Scilex Holding Company Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.51 - 5.59
52 Week Range	3.60 - 80.50
Beta	1.98
Implied Volatility	276.14%
IV Rank	55.53%
Day's Volume	367,624
Average Volume	70,720
Shares Outstanding	6,942,860
Market Cap	32,909,156
Sector	Healthcare
Industry	Drug Manufacturers - General
IPO Date	2021-03-05

Valuation
Profitability
Growth
Health
P/E Ratio	-0.22
Forward P/E Ratio	N/A
EPS	-21.35
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	113
Country	USA
Website	SCLX

Scilex Holding Co is engaged in the development and commercialization of non-opioid pain management products. The company's lead product ZTlido.

SCLX's peers: AZN, HZNP, GILD, BMY, AMGN, LLY, ABBV, MRK, BIIB, SNY, NVS, GSK

*Chart delayed

Analyzing fundamentals for SCLX we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see SCLX Fundamentals page.

Watching at SCLX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on SCLX Technicals page.